Effect of end-induction MRD on outcome by therapeutic protocol and NCI risk group
Study/risk group . | 5-y EFS, % ± SE (no.) . | |
---|---|---|
MRD− . | MRD+ (> .01%)* . | |
9904/SR | 95 ± 1 (668) | 64 ± 7 (105) |
9905/SR | 89 ± 2 (464) | 59 ± 6 (119) |
9905/HR | 79 ± 4 (295) | 33 ± 8 (74) |
9906/HR† | 72 ± 5 (161) | 34 ± 8 (85) |
Study/risk group . | 5-y EFS, % ± SE (no.) . | |
---|---|---|
MRD− . | MRD+ (> .01%)* . | |
9904/SR | 95 ± 1 (668) | 64 ± 7 (105) |
9905/SR | 89 ± 2 (464) | 59 ± 6 (119) |
9905/HR | 79 ± 4 (295) | 33 ± 8 (74) |
9906/HR† | 72 ± 5 (161) | 34 ± 8 (85) |